A new medicine, TP-317, for Ulcerative Colitis
Development of TP-317 in Ulcerative Colitis
This research focuses on creating an oral medicine called TP-317 to help people with ulcerative colitis manage their symptoms and stay in remission.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thetis Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Deep River, United States) |
| Project ID | NIH-11056022 on NIH RePORTER |
What this research studies
Ulcerative colitis is a long-lasting condition causing inflammation and sores in the colon and rectum, affecting many people in the United States. It's believed to happen when the body's immune system overreacts to gut bacteria, leading to ongoing inflammation. This new medicine, TP-317, is designed to mimic natural body compounds that help resolve inflammation. The goal is to offer an effective oral treatment that can both calm flare-ups and prevent them from returning.
Who could benefit from this research
Good fit: Patients with ulcerative colitis who are looking for new oral treatment options to manage their chronic inflammation and achieve remission may be interested in this research.
Not a fit: Patients without ulcerative colitis or those whose condition is not related to the inflammatory pathways targeted by this medicine may not receive benefit.
Why it matters
Potential benefit: If successful, this medicine could provide a new, stable, and easy-to-take oral treatment option for patients living with ulcerative colitis.
How similar studies have performed: Previous studies in animal models of ulcerative colitis have shown that the active component of TP-317, Resolvin E1, is effective, and prior grant funding successfully completed initial drug development steps.
Where this research is happening
Deep River, United States
- Thetis Pharmaceuticals, LLC — Deep River, United States (Active)
Researchers
- Principal investigator: Parkinson, John — Thetis Pharmaceuticals, LLC
- Study coordinator: Parkinson, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.